Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1997 Sep;71(9):6547–6554. doi: 10.1128/jvi.71.9.6547-6554.1997

Activation domain requirements for disruption of Epstein-Barr virus latency by ZEBRA.

S Asković 1, R Baumann 1
PMCID: PMC191931  PMID: 9261375

Abstract

Latent infection of B lymphocytes by Epstein-Barr virus (EBV) can be disrupted by expression of the EBV ZEBRA protein. ZEBRA, a transcriptional activator, initiates the EBV lytic cascade by activating viral gene expression. ZEBRA is also indispensable for viral replication and binds directly to the EBV lytic origin of replication. The studies described herein demonstrate that the activation domain. ZEBRA activation can be replaced by a heterologous acidic, proline-rich, or glutamine-rich activation domain. ZEBRA activation domain swap constructs retain ZEBRA's native abilities to activate specific EBV promoters, to disrupt EBV latency, and to stimulate replication at the EBV lytic origin. Additional work, employing sequential and internal deletions of ZEBRA's N-terminal activation domain, indicates that its separate activities are not attributable to specific subdomains but are spread throughout its N terminus and therefore cannot be inactivated by deleting localized regions.

Full Text

The Full Text of this article is available as a PDF (1.9 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altschul S. F., Gish W., Miller W., Myers E. W., Lipman D. J. Basic local alignment search tool. J Mol Biol. 1990 Oct 5;215(3):403–410. doi: 10.1016/S0022-2836(05)80360-2. [DOI] [PubMed] [Google Scholar]
  2. Asković S., Baumann R. Alternative system for detection and mapping of activation domains. Biotechniques. 1997 May;22(5):948–951. doi: 10.2144/97225rr02. [DOI] [PubMed] [Google Scholar]
  3. Baumann R., Grogan E., Ptashne M., Miller G. Changing Epstein-Barr viral ZEBRA protein into a more powerful activator enhances its capacity to disrupt latency. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4436–4440. doi: 10.1073/pnas.90.10.4436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Baumann R., Warren G., Askovic S. Restoration of the Epstein-Barr virus ZEBRA protein's capacity to disrupt latency by the addition of heterologous activation regions. Virology. 1995 Aug 1;211(1):64–72. doi: 10.1006/viro.1995.1379. [DOI] [PubMed] [Google Scholar]
  5. Cayrol C., Flemington E. K. Identification of cellular target genes of the Epstein-Barr virus transactivator Zta: activation of transforming growth factor beta igh3 (TGF-beta igh3) and TGF-beta 1. J Virol. 1995 Jul;69(7):4206–4212. doi: 10.1128/jvi.69.7.4206-4212.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cayrol C., Flemington E. K. The Epstein-Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors. EMBO J. 1996 Jun 3;15(11):2748–2759. [PMC free article] [PubMed] [Google Scholar]
  7. Cayrol C., Flemington E. G0/G1 growth arrest mediated by a region encompassing the basic leucine zipper (bZIP) domain of the Epstein-Barr virus transactivator Zta. J Biol Chem. 1996 Dec 13;271(50):31799–31802. doi: 10.1074/jbc.271.50.31799. [DOI] [PubMed] [Google Scholar]
  8. Chavrier P., Gruffat H., Chevallier-Greco A., Buisson M., Sergeant A. The Epstein-Barr virus (EBV) early promoter DR contains a cis-acting element responsive to the EBV transactivator EB1 and an enhancer with constitutive and inducible activities. J Virol. 1989 Feb;63(2):607–614. doi: 10.1128/jvi.63.2.607-614.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chevallier-Greco A., Gruffat H., Manet E., Calender A., Sergeant A. The Epstein-Barr virus (EBV) DR enhancer contains two functionally different domains: domain A is constitutive and cell specific, domain B is transactivated by the EBV early protein R. J Virol. 1989 Feb;63(2):615–623. doi: 10.1128/jvi.63.2.615-623.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Chevallier-Greco A., Manet E., Chavrier P., Mosnier C., Daillie J., Sergeant A. Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter. EMBO J. 1986 Dec 1;5(12):3243–3249. doi: 10.1002/j.1460-2075.1986.tb04635.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Chi T., Carey M. The ZEBRA activation domain: modular organization and mechanism of action. Mol Cell Biol. 1993 Nov;13(11):7045–7055. doi: 10.1128/mcb.13.11.7045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Countryman J., Miller G. Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci U S A. 1985 Jun;82(12):4085–4089. doi: 10.1073/pnas.82.12.4085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cox M. A., Leahy J., Hardwick J. M. An enhancer within the divergent promoter of Epstein-Barr virus responds synergistically to the R and Z transactivators. J Virol. 1990 Jan;64(1):313–321. doi: 10.1128/jvi.64.1.313-321.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Davis M. G., Huang E. S. Transfer and expression of plasmids containing human cytomegalovirus immediate-early gene 1 promoter-enhancer sequences in eukaryotic and prokaryotic cells. Biotechnol Appl Biochem. 1988 Feb;10(1):6–12. [PubMed] [Google Scholar]
  15. Fixman E. D., Hayward G. S., Hayward S. D. Replication of Epstein-Barr virus oriLyt: lack of a dedicated virally encoded origin-binding protein and dependence on Zta in cotransfection assays. J Virol. 1995 May;69(5):2998–3006. doi: 10.1128/jvi.69.5.2998-3006.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Fixman E. D., Hayward G. S., Hayward S. D. trans-acting requirements for replication of Epstein-Barr virus ori-Lyt. J Virol. 1992 Aug;66(8):5030–5039. doi: 10.1128/jvi.66.8.5030-5039.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Flemington E. K., Borras A. M., Lytle J. P., Speck S. H. Characterization of the Epstein-Barr virus BZLF1 protein transactivation domain. J Virol. 1992 Feb;66(2):922–929. doi: 10.1128/jvi.66.2.922-929.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Giot J. F., Mikaelian I., Buisson M., Manet E., Joab I., Nicolas J. C., Sergeant A. Transcriptional interference between the EBV transcription factors EB1 and R: both DNA-binding and activation domains of EB1 are required. Nucleic Acids Res. 1991 Mar 25;19(6):1251–1258. doi: 10.1093/nar/19.6.1251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Gruffat H., Moreno N., Sergeant A. The Epstein-Barr virus (EBV) ORI1yt enhancer is not B-cell specific and does not respond synergistically to the EBV transcription factors R and Z. J Virol. 1990 Jun;64(6):2810–2818. doi: 10.1128/jvi.64.6.2810-2818.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Gutsch D. E., Holley-Guthrie E. A., Zhang Q., Stein B., Blanar M. A., Baldwin A. S., Kenney S. C. The bZIP transactivator of Epstein-Barr virus, BZLF1, functionally and physically interacts with the p65 subunit of NF-kappa B. Mol Cell Biol. 1994 Mar;14(3):1939–1948. doi: 10.1128/mcb.14.3.1939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Hammerschmidt W., Sugden B. Identification and characterization of oriLyt, a lytic origin of DNA replication of Epstein-Barr virus. Cell. 1988 Nov 4;55(3):427–433. doi: 10.1016/0092-8674(88)90028-1. [DOI] [PubMed] [Google Scholar]
  22. Hardwick J. M., Lieberman P. M., Hayward S. D. A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J Virol. 1988 Jul;62(7):2274–2284. doi: 10.1128/jvi.62.7.2274-2284.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Hatfull G., Bankier A. T., Barrell B. G., Farrell P. J. Sequence analysis of Raji Epstein-Barr virus DNA. Virology. 1988 Jun;164(2):334–340. doi: 10.1016/0042-6822(88)90546-6. [DOI] [PubMed] [Google Scholar]
  24. Hoey T., Weinzierl R. O., Gill G., Chen J. L., Dynlacht B. D., Tjian R. Molecular cloning and functional analysis of Drosophila TAF110 reveal properties expected of coactivators. Cell. 1993 Jan 29;72(2):247–260. doi: 10.1016/0092-8674(93)90664-c. [DOI] [PubMed] [Google Scholar]
  25. Kenney S., Kamine J., Holley-Guthrie E., Lin J. C., Mar E. C., Pagano J. The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters. J Virol. 1989 Apr;63(4):1729–1736. doi: 10.1128/jvi.63.4.1729-1736.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Kolman J. L., Taylor N., Gradoville L., Countryman J., Miller G. Comparing transcriptional activation and autostimulation by ZEBRA and ZEBRA/c-Fos chimeras. J Virol. 1996 Mar;70(3):1493–1504. doi: 10.1128/jvi.70.3.1493-1504.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Le Roux F., Sergeant A., Corbo L. Epstein-Barr virus (EBV) EB1/Zta protein provided in trans and competent for the activation of productive cycle genes does not activate the BZLF1 gene in the EBV genome. J Gen Virol. 1996 Mar;77(Pt 3):501–509. doi: 10.1099/0022-1317-77-3-501. [DOI] [PubMed] [Google Scholar]
  28. Lieberman P. M., Berk A. J. The Zta trans-activator protein stabilizes TFIID association with promoter DNA by direct protein-protein interaction. Genes Dev. 1991 Dec;5(12B):2441–2454. doi: 10.1101/gad.5.12b.2441. [DOI] [PubMed] [Google Scholar]
  29. Lieberman P. M., Hardwick J. M., Hayward S. D. Responsiveness of the Epstein-Barr virus NotI repeat promoter to the Z transactivator is mediated in a cell-type-specific manner by two independent signal regions. J Virol. 1989 Jul;63(7):3040–3050. doi: 10.1128/jvi.63.7.3040-3050.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Lieberman P. M., Hardwick J. M., Sample J., Hayward G. S., Hayward S. D. The zta transactivator involved in induction of lytic cycle gene expression in Epstein-Barr virus-infected lymphocytes binds to both AP-1 and ZRE sites in target promoter and enhancer regions. J Virol. 1990 Mar;64(3):1143–1155. doi: 10.1128/jvi.64.3.1143-1155.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Marshall D., Sample C. Epstein-Barr virus nuclear antigen 3C is a transcriptional regulator. J Virol. 1995 Jun;69(6):3624–3630. doi: 10.1128/jvi.69.6.3624-3630.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Mitchell P. J., Tjian R. Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins. Science. 1989 Jul 28;245(4916):371–378. doi: 10.1126/science.2667136. [DOI] [PubMed] [Google Scholar]
  33. Qian Z., Brunovskis P., Rauscher F., 3rd, Lee L., Kung H. J. Transactivation activity of Meq, a Marek's disease herpesvirus bZIP protein persistently expressed in latently infected transformed T cells. J Virol. 1995 Jul;69(7):4037–4044. doi: 10.1128/jvi.69.7.4037-4044.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Rabson M., Heston L., Miller G. Identification of a rare Epstein-Barr virus variant that enhances early antigen expression in Raji cells. Proc Natl Acad Sci U S A. 1983 May;80(9):2762–2766. doi: 10.1073/pnas.80.9.2762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Rooney C. M., Rowe D. T., Ragot T., Farrell P. J. The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J Virol. 1989 Jul;63(7):3109–3116. doi: 10.1128/jvi.63.7.3109-3116.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Sarisky R. T., Gao Z., Lieberman P. M., Fixman E. D., Hayward G. S., Hayward S. D. A replication function associated with the activation domain of the Epstein-Barr virus Zta transactivator. J Virol. 1996 Dec;70(12):8340–8347. doi: 10.1128/jvi.70.12.8340-8347.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Schepers A., Pich D., Hammerschmidt W. A transcription factor with homology to the AP-1 family links RNA transcription and DNA replication in the lytic cycle of Epstein-Barr virus. EMBO J. 1993 Oct;12(10):3921–3929. doi: 10.1002/j.1460-2075.1993.tb06070.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Schepers A., Pich D., Hammerschmidt W. Activation of oriLyt, the lytic origin of DNA replication of Epstein-Barr virus, by BZLF1. Virology. 1996 Jun 15;220(2):367–376. doi: 10.1006/viro.1996.0325. [DOI] [PubMed] [Google Scholar]
  39. Schepers A., Pich D., Mankertz J., Hammerschmidt W. cis-acting elements in the lytic origin of DNA replication of Epstein-Barr virus. J Virol. 1993 Jul;67(7):4237–4245. doi: 10.1128/jvi.67.7.4237-4245.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Sista N. D., Pagano J. S., Liao W., Kenney S. Retinoic acid is a negative regulator of the Epstein-Barr virus protein (BZLF1) that mediates disruption of latent infection. Proc Natl Acad Sci U S A. 1993 May 1;90(9):3894–3898. doi: 10.1073/pnas.90.9.3894. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Taylor N., Countryman J., Rooney C., Katz D., Miller G. Expression of the BZLF1 latency-disrupting gene differs in standard and defective Epstein-Barr viruses. J Virol. 1989 Apr;63(4):1721–1728. doi: 10.1128/jvi.63.4.1721-1728.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Yates J., Warren N., Reisman D., Sugden B. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci U S A. 1984 Jun;81(12):3806–3810. doi: 10.1073/pnas.81.12.3806. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Zalani S., Holley-Guthrie E., Kenney S. Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9194–9199. doi: 10.1073/pnas.93.17.9194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Zhang Q., Gutsch D., Kenney S. Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol Cell Biol. 1994 Mar;14(3):1929–1938. doi: 10.1128/mcb.14.3.1929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Zhang Q., Hong Y., Dorsky D., Holley-Guthrie E., Zalani S., Elshiekh N. A., Kiehl A., Le T., Kenney S. Functional and physical interactions between the Epstein-Barr virus (EBV) proteins BZLF1 and BMRF1: Effects on EBV transcription and lytic replication. J Virol. 1996 Aug;70(8):5131–5142. doi: 10.1128/jvi.70.8.5131-5142.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES